CagriSema diabetes trials REIMAGINE 1-3 show HbA1c and weight reductions at ADA 2026

Novo Nordisk presented REIMAGINE 1 to 3 data for CagriSema 2.4 mg/2.4 mg in type 2 diabetes at the ADA Scientific Sessions in New Orleans, June 5 to 8, 2026. All CagriSema-versus-placebo comparisons were statistically significant, with HbA1c falling 1.8% to 2.3% and weight 12% to 14%. The trials widen the CagriSema story beyond obesity, but the US obesity decision remains the bigger stock catalyst.

• REIMAGINE 1: HbA1c -1.8%, weight -13.8% (40 weeks)
• REIMAGINE 2: HbA1c -1.91%, weight -14.2% (68 weeks), better than semaglutide 2.4 mg
• REIMAGINE 3: HbA1c -2.33%, weight -12.0% (40 weeks, on basal insulin)
• Gastrointestinal side effects were the most common adverse events